Medical Oncology

Prof. Dr. Mutlu Demiray

Doctor and researcher Medicana Zincirlikuyu İstanbul
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

CV

Education and experience

From source

Experience

  • 2014-HalenMedicana Sağlık Grubu (Prof. Dr.)medicana.com.tr
  • 2013-2014Almanya İntegratif Onkoloji Eğitimi, Serbest Hekimlik (Doç. Dr.)medicana.com.tr
  • 2011-2013OSM Ortadoğu Hastanesi (Doç. Dr.)medicana.com.tr
  • 2010-2011İstanbul İtalyan Hastanesi (Doç. Dr.)medicana.com.tr
  • 2007-2010Medical Park Bursa Hastanesi (Doç. Dr.)medicana.com.tr
  • 2006-2007Ali Osman Sönmez Onkoloji Hastanesi (Doç. Dr.)medicana.com.tr
  • 2004-2006Uludağ Üniversitesi (Uzm. Dr.)medicana.com.tr

Education

  • 1995Akdeniz Üniversitesi Tıp Fakültesimedicana.com.tr
  • 2005Uludağ Üniversite Tıp Fakültesimedicana.com.tr
  • 2000İç Hastalıklarımedicana.com.tr
  • 2004Tıbbi Onkolojimedicana.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologymedicana.com.trFrom source
  • Department name at the sourceMedikal Onkolojimedicana.com.trFrom source
  • InstitutionMedicana Zincirlikuyumedicana.com.trFrom source
  • Publications87 publicationsmedicana.com.tr profile pageFrom source
  • Last synchronised7 November 2026 03:27https://www.medicana.com.tr/hekim-detay/21886/mutlu-demiraymedicana.com.tr

Scientific work

Publications

87 publications

  1. E. Ulusal Bilimsel Toplantılarda Sunulan ve Bildiri Kitaplarında Basılan Bildiriler

    Source: medicana.com.tr profile page

  2. (Yukarıdaki maddelerde yer alan başlıklardaki kategorilere girmeyen ve belirtilmek istenen tüm eserler bu maddenin altında belirtilecektir.)

    Source: medicana.com.tr profile page

  3. B. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitaplarında (Proceedings) basılan bildiriler

    Source: medicana.com.tr profile page

  4. DNA Repair Deficiency: A Series of 8 Patients. Integr Cancer Ther. 2020 Jan-Dec;19:1534735420969812. doi: 10.1177/1534735420969812. PMID: 33150793.

    Source: medicana.com.tr profile page

  5. A2. Bahadori F, Demiray M. Management of extravasation of oxaliplatin by mimicking its biotransformation. Clin Transl Oncol. 2018 Oct;20(10):1353-1357. doi: 10.1007/s12094-018-1854-z. Epub 2018 Apr 27. PMID: 29704231.

    Source: medicana.com.tr profile page

  6. A3. Sahinbas H, Rosch M, Demiray M. Temperature measurements in a capacitive system of deep loco-regional hyperthermia. Electromagn Biol Med. 2017;36(3):248-258. doi: 10.1080/15368378.2017.1307221. Epub 2017 Apr 27. PMID: 28448752.

    Source: medicana.com.tr profile page

  7. A4. Bahadori F, Demiray M. A Realistic View on "The Essential Medicinal Chemistry of Curcumin". ACS Med Chem Lett. 2017 Sep 14;8(9):893-896. doi: 10.1021/acsmedchemlett.7b00284. PMID: 28947929; PMCID: PMC5601379.

    Source: medicana.com.tr profile page

  8. A5. Demiray M, Sahinbas H, Atahan S, Demiray H, Selcuk D, Yildirim I, Atayoglu AT. Successful treatment of c-kit-positive metastatic Adenoid Cystic Carcinoma (ACC) with a combination of curcumin plus imatinib: A case report. Complement Ther Med. 2016 Aug;27:108-13. doi: 10.1016/j.ctim.2016.06.009. Epub 2016 Jul 1. PMID: 27515884.

    Source: medicana.com.tr profile page

  9. A6. Arican A, Bozkurt T, Bozcuk H, Demirkan B, Buyukberber S, Alkis N, Sanli UA, Camci C, Yildiz M, Yucel I, Uygun K, Aslay I, Demiray M, Bese NS, Isikdogan A, Bahat Z, Gemici C, Ozdemir F, Ozdener F, Pekin B. A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support Care Cancer. 2014 Oct;22(10):2629-34. doi: 10.1007/s00520-014-2253-9. Epub 2014 Apr 22. PMID: 24752566; PMCID: PMC4153980.

    Source: medicana.com.tr profile page

  10. A7. Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, Evrensel T, Manavoglu O. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest. 2006 Nov;24(7):669-76. doi: 10.1080/07357900600981307. PMID: 17118776.

    Source: medicana.com.tr profile page

View all 87 publications